Navigation Links
Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
Date:9/13/2011

LISBON, Portugal, Sept. 13, 2011 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) presented results today demonstrating its novel insulin sensitizers, MSDC-0160 and MSDC-0602, stimulate progenitor cells within subcutaneous fat tissue to become brown-like fat cells instead of white fat cells. Brown fat, which diminishes with age, burns calories while white fat stores calories. The mechanism of action by which MSDC-0160 and MSDC-0602 cause these effects is independent of the activation PPARy, a factor that drives the expansion of white fat. These findings suggest the potential for minimizing weight gain normally associated with currently marketed insulin sensitizers, and may result in weight loss in longer duration clinical studies. The data were presented in an oral presentation at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal.

MSDC-0160 and MSDC-0602 are novel insulin sensitizers that are selective for mTOT, a mitochondrial molecular target that functions as a "switch" connecting mitochondrial metabolism to important cell functions.  Previous studies have shown the PPAR-independent pharmacology of each of these compounds results in improved insulin action, preservation of beta cell function, and generation of brown fat. The amount of brown fat is inversely proportioned to body weight (and white fat).

"Given the novel mechanism of action of our compounds, we expect to see weight control over longer duration treatments with these new clinical candidates as a result of the "browning" of adipose or fat stores," said Jerry Colca, Ph.D., president and Chief Scientific Officer of MSDC. "These results in the preclinical setting have important mechanistic implications for developing future therapies and provide a framework for further defining the mTOT biochemical pathway."

Study Methodology and Key Results

In this in vitro study, progenitor cells from axillary adipose depots (fat tissue located in the armpit region) were isolated from mice and placed in tissue culture under defined conditions. Treatment of these cells with micromolar concentrations of the MSDC compounds elicited a time- and dose-dependent differentiation of the progenitor cells into brown-like adipose cells. The brown-like adipose cells express UCP1 message and protein in a process that includes increased mitochondrial biogenesis. These effects were not attenuated by the potent PPARy antagonists, T0070907 and GW9662, confirming the PPAR-independent pharmacology of the MSDC compound.  Importantly, the cells from axillary adipose depots also secreted the insulin-sensitizing hormone adiponectin in response to the MSDC compounds. These results show that novel insulin sensitizers that increase brown fat could have important implications for the development of new therapies to treat type 2 diabetes.

About Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and new therapies for metabolic diseases associated with mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised more than $55 million to support development of its lead compounds MSDC-0160 and MSDC-0602.


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolic Solutions Development Company Receives $773,000 From the Alzheimers Drug Discovery Foundation to Fund Phase 2a Trial
2. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
3. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
4. Bariatric Advantage to Attend American Society of Metabolic and Bariatric Surgery (ASMBS) Conference
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management
7. Atherotech Unveils New Cardiometabolic Test Panels
8. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
11. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Muse bio, a privately-held company leading the development of ... Kevin Ness has been appointed Chief Executive Officer ... Kevin succeeds Muse bio,s founding CEO Ryan ... as well as remains Slade Professor, Chemical and Biological ... the RAS Energy Institute at the University of Colorado, ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO ... online shopping cart. The new website has been designed to provide the best ... allow customers to access detailed product information, read educational industry content as well ...
(Date:12/6/2016)... PA (PRWEB) , ... December ... ... part of the Almac Group, the world’s largest privately-held contract pharmaceutical development ... with inVentiv Health, a leading biopharma outsourcing company combining a leading CRO ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... company, today announced it has acquired the assets of Theorem Clinical Research ... and focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution ...
Breaking Biology Technology:
(Date:11/16/2016)... SANTA CLARA, Calif. , Nov. 16, 2016 /PRNewswire/ ... company enhancing user experience and security for consumer ... provider for the financial and retail industry, today ... more secure and convenient way to authenticate users ... now uses Sensory,s TrulySecure™ software which ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
Breaking Biology News(10 mins):